A conversation with Ben Fairfax about the recent article: CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
This episode discusses Milotay, G., Little, M., Watson, R.A. et al. CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade. Nat Med (2025). https://doi.org/10.1038/s41591-025-03647-1.
